Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

916
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
916
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paraneoplastic Motor Neuropathy in Nodular Sclerosis Hodgkin's Lymphoma: Case Report.

Case reports in hematology·2026
Same author

Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Blood advances·2026
Same author

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Blood·2026
Same author

Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty.

Journal of geriatric oncology·2026
Same author

Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study.

Blood advances·2026

Related Experiment Video

Updated: Apr 11, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.7K

Treating Burkitt Lymphoma in Adults.

Carla Casulo1, Jonathan Friedberg

  • 1Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA, Carla_Casulo@URMC.Rochester.edu.

Current Hematologic Malignancy Reports
|May 28, 2015
PubMed
Summary

Burkitt lymphoma is an aggressive B-cell cancer characterized by MYC oncogene translocations. While intensive treatments offer cures for many, prognosis remains poor for elderly or relapsed patients.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Burkitt lymphoma is an aggressive B-cell lymphoma.
  • It is characterized by MYC oncogene translocations.
  • Three subtypes exist: endemic (EBV-associated), sporadic, and immunodeficiency-associated (HIV-associated).

Purpose of the Study:

  • To provide an overview of Burkitt lymphoma.
  • To discuss its subtypes, histological features, and molecular characteristics.
  • To highlight recent advances in understanding and treatment outcomes.

Main Methods:

  • Review of existing literature on Burkitt lymphoma.
  • Analysis of histological and molecular data.
  • Discussion of epidemiological and clinical findings.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Related Experiment Videos

Last Updated: Apr 11, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.7K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Main Results:

  • Histologically, it presents as diffuse, intermediate-sized B cells with high proliferation.
  • Transcriptional profiling has enhanced molecular understanding and mutational landscape characterization.
  • Most patients achieve remission with intensive therapy, but outcomes are worse in elderly or relapsed cases.

Conclusions:

  • Burkitt lymphoma requires intensive treatment strategies.
  • Further research into its molecular basis may improve therapeutic approaches.
  • Prognosis is significantly influenced by patient age and disease status (relapsed vs. initial).